Melanoma, Version 4.2014

Restricted access

The NCCN Guidelines for Melanoma provide multidisciplinary recommendations for the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease.

Provided content development and/or authorship assistance.

  • 1.

    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:929.

  • 2.

    Jemal A, Saraiya M, Patel P. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. J Am Acad Dermatol 2011;65(Suppl 1):S17-25.e11-13.

    • Search Google Scholar
    • Export Citation
  • 3.

    Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:43404346.

  • 4.

    Agrawal S, Kane JM III, Guadagnolo BA. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. Cancer 2009;115:58365844.

    • Search Google Scholar
    • Export Citation
  • 5.

    Burmeister BH, Henderson MA, Ainslie J. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012;13:589597.

    • Search Google Scholar
    • Export Citation
  • 6.

    Henderson MA, Burmeister B, Ainslie J. Adjuvant radiotherapy after lymphadenectomy in melanoma patients: final results of an intergroup randomized trial (ANZMTG 0.1.02/TROG 02.01) [abstract]. J Clin Oncol 2013;31(Suppl 15):Abstract 9001.

    • Search Google Scholar
    • Export Citation
  • 7.

    Beadle BM, Guadagnolo BA, Ballo MT. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2009;73:13761382.

    • Search Google Scholar
    • Export Citation
  • 8.

    Chang DT, Amdur RJ, Morris CG, Mendenhall WM. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. Int J Radiat Oncol Biol Phys 2006;66:10511055.

    • Search Google Scholar
    • Export Citation
  • 9.

    Sause WT, Cooper JS, Rush S. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991;20:429432.

    • Search Google Scholar
    • Export Citation
  • 10.

    Conill C, Jorcano S, Domingo-Domenech J. Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b in high-risk melanoma patients. Melanoma Res 2007;17:304309.

    • Search Google Scholar
    • Export Citation
  • 11.

    Hofmann M, Kiecker F, Wurm R. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol 2006;76:5964.

    • Search Google Scholar
    • Export Citation
  • 12.

    Margolin K, Atkins B, Thompson A. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 2002;128:214218.

    • Search Google Scholar
    • Export Citation
  • 13.

    Long GV, Menzies AM, Nagrial AM. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29:12391246.

    • Search Google Scholar
    • Export Citation
  • 14.

    Hauschild A, Grob JJ, Demidov LV. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma [abstract]. J Clin Oncol 2012;30(Suppl 18):Abstract LBA8500.

    • Search Google Scholar
    • Export Citation
  • 15.

    Long GV, Trefzer U, Davies MA. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:10871095.

    • Search Google Scholar
    • Export Citation
  • 16.

    Flaherty KT, Robert C, Hersey P. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107114.

  • 17.

    Kim KB, Kefford R, Pavlick AC. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31:482489.

    • Search Google Scholar
    • Export Citation
  • 18.

    Chapman PB, Hauschild A, Robert C. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:25072516.

  • 19.

    Hauschild A, Grob JJ, Demidov LV. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358365.

    • Search Google Scholar
    • Export Citation
  • 20.

    Sosman JA, Kim KB, Schuchter L. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707714.

  • 21.

    Su F, Viros A, Milagre C. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207215.

    • Search Google Scholar
    • Export Citation
  • 22.

    Flaherty KT, Infante JR, Daud A. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:16941703.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 270 142 6
PDF Downloads 49 40 3
EPUB Downloads 0 0 0